FUSED PENTACYCLIC IMIDAZOLE DERIVATIVES

• Main Authors: Quincey, Joanna Rachel, Deligny, Michael, Shaw, Michael Alan, Keyaerts, Jean, Jadot, Sophie, Mac Coss, Malcolm, Swinnen, Dominique Louis Léon, Zhu, Zhaoning, Brookings, Daniel Christopher, Hutchings, Martin Clive, Foricher, Yann, Filoche-Romme, Bruno, Calmiano, Mark Daniel, Schio, Laurent, Heer, Jag Paul, Selby, Matthew Duncan, Xuan, Mengyang, Evrard, Yves, De Haro Garcia, Teresa, Johnson, James Andrew
• Format: Patent
• Language: Croatian; English
• Published: 21.01.2022
• Subjects: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM; CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.